Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.71)
# 156
Out of 5,182 analysts
140
Total ratings
56.35%
Success rate
43.65%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Upgrades: Buy | $3 → $9 | $3.60 | +150.00% | 3 | Apr 10, 2026 | |
| TBPH Theravance Biopharma | Maintains: Neutral | $14 → $17 | $16.35 | +3.98% | 3 | Apr 7, 2026 | |
| HROW Harrow | Reiterates: Buy | $74 → $65 | $35.93 | +80.91% | 5 | Apr 7, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $3 → $4 | $1.48 | +170.27% | 3 | Mar 25, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $26 | $8.41 | +209.16% | 1 | Mar 24, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $22 | $8.36 | +163.16% | 3 | Mar 18, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $77.50 | +93.55% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $65.01 | +66.13% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $5.36 | +67.91% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $39.48 | +6.38% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 → $40 | $26.32 | +51.98% | 2 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.60 | +160.87% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 → $16 | $8.12 | +97.04% | 20 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $560 | $519.61 | +7.77% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $33.73 | +63.06% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.72 | +1,062.79% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $3.24 | +455.56% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.49 | +236.70% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $13.19 | +51.63% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $19.23 | +82.01% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $65.14 | -41.66% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $34.26 | +180.21% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $0.90 | +65.82% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $6.80 | +1,958.82% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.10 | +2,095.12% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.96 | +3,940.40% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.80 | +177.78% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.35 | +3,729.79% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.18 | +493.22% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.70 | +642,757.14% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.35 | +199,900.00% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.74 | +194,231.98% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.30 | +73.91% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $88.77 | -56.07% | 2 | Mar 18, 2020 |
MacroGenics
Apr 10, 2026
Upgrades: Buy
Price Target: $3 → $9
Current: $3.60
Upside: +150.00%
Theravance Biopharma
Apr 7, 2026
Maintains: Neutral
Price Target: $14 → $17
Current: $16.35
Upside: +3.98%
Harrow
Apr 7, 2026
Reiterates: Buy
Price Target: $74 → $65
Current: $35.93
Upside: +80.91%
Lineage Cell Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $3 → $4
Current: $1.48
Upside: +170.27%
Climb Bio
Mar 24, 2026
Initiates: Buy
Price Target: $26
Current: $8.41
Upside: +209.16%
Arcturus Therapeutics Holdings
Mar 18, 2026
Initiates: Buy
Price Target: $22
Current: $8.36
Upside: +163.16%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $77.50
Upside: +93.55%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $65.01
Upside: +66.13%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $5.36
Upside: +67.91%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $39.48
Upside: +6.38%
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $26.32
Upside: +51.98%
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.60
Upside: +160.87%
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $8.12
Upside: +97.04%
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $519.61
Upside: +7.77%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $33.73
Upside: +63.06%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $1.72
Upside: +1,062.79%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.24
Upside: +455.56%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.49
Upside: +236.70%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $13.19
Upside: +51.63%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $19.23
Upside: +82.01%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $65.14
Upside: -41.66%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $34.26
Upside: +180.21%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.90
Upside: +65.82%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $6.80
Upside: +1,958.82%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.10
Upside: +2,095.12%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.96
Upside: +3,940.40%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.80
Upside: +177.78%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.35
Upside: +3,729.79%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.18
Upside: +493.22%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.70
Upside: +642,757.14%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.35
Upside: +199,900.00%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.74
Upside: +194,231.98%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.30
Upside: +73.91%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $88.77
Upside: -56.07%